Objective: To assess the severity of anxiety and depression in patients selected for treatment with the magnetic resonance-guided focused ultrasound thalamotomy (MRgFUS TT) before the therapy (1, 2, 3).

Background: Anxiety (A) and depression (D) in patients with Parkinson’s disease (PD) are underestimated and not paid enough attention conditions, which could interfere with treatment.

Method: 19 patients with PD were evaluated with Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment scale (MoCA) before they underwent MRgFUS TT.

Results: 4 women and 15 men were enrolled, mean age 61.78 years old (min – 38 y.o., max- 81y.o.). Median of disease duration was 6.38 years (min-2, max-13), median MoCA points were 25.73 (min – 21, max–30). A and D were found in 6 patients (31.58 %). The median severity of A was 6.26 points (min-1, max-14), of D was 5.68 points (min-0, max-12). A and D within normal ranges were in 13 patients. Clinically remarkable points of A were in 2 patients, of D – in 4 patients.  Borderline abnormal ranges of A were in 4 patients, of D – in 1. The levels of anxiety and depression were not correlated with each other and statistically significant correlated with disease duration, modified Hoen and Yarh stage (m-HYS), p<0.05. 4 patients with D more than 11 HADS points were in 3 and 4 stages on the m-HYS. 13 patients with normal A and D HADS score were in the 2-2.5 stages on this scale. Limitations of our study: predominance of tremor over rigidity, heterogeneity and small sample size.

Conclusion: A and D are common in PD. It is necessary to evaluate A and D with more detailed and sensitive scales (Montgomery—Asberg Depression Rating Scale, Hamilton scale, Beck scale). It is demanded to increase the sample size and to continue evaluation of A and D in the follow-up period after the MRgFUS TT.  It would be desirable to compare the prevalence of A and D in patients with a predominantly rigid form of PD before and after the MRgFUS TT.

References: 1. Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2007). A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders, 23(2), 183–189. 2. Yang-Pei Changz, Min-Sheng Lee, Da-Wei Wu, Jui-Hsiu Tsai, Pei-Shan Ho, Chun-Hung Richard Lin, Hung-Yi Chuang. Risk factors for depression in patients with Parkinson’s disease: A nationwide nested case-control study. PLoS One. 2020; 15(7): e0236443.Published online 2020 Jul 27. doi: 10.1371/journal.pone.0236443 3. V. Lo Buono, R. Palmeri, S. De Salvo, M. Berenati, A. Greco, R. Ciurleo, C. Sorbera, V. Cimino, F. Corallo, P. Bramanti, S. Marino, G. Di Lorenzo, L. Bonanno. Anxiety, depression, and quality of life in Parkinson’s disease: the implications of multidisciplinary treatmen Neural Regeneration Research, Vol 16, No.3, March 2021, 587-590.

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/anxiety-and-depression-in-patients-with-parkinsons-disease-selected-for-magnetic-resonance-guided-focused-ultrasound-thalamotomy/